Procept Biorobotics Corp
NASDAQ:PRCT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
27.89
74.69
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Procept Biorobotics Corp
Procept Biorobotics Corp. is a pioneering force in the medical technology landscape, blending innovative engineering with clinical insights to address some of the most pressing challenges in urology. Founded with a vision to revolutionize surgical care, the company developed the AquaBeam Robotic System, an advanced medical platform that leverages robotic precision and real-time ultrasound imaging. This system is primarily employed in performing Aquablation therapy, a minimally invasive treatment designed to alleviate symptoms of benign prostatic hyperplasia (BPH). By integrating robotics and imaging, Procept offers a solution that enhances the accuracy of prostate tissue removal while minimizing risks and downtime for patients—a significant advancement over conventional methods.
Revenue generation for Procept Biorobotics centers on the sales of their AquaBeam systems, along with consumables and service contracts that provide ongoing support and upgrades for their hospital and clinical partners. Recognizing the critical nature of procedure efficiency and safety, the company also invests in broadening the application of its technology and frequently seeks endorsements through clinical trials and studies to validate their innovations. By ensuring their cutting-edge solutions meet the stringent demands of healthcare professionals and patients alike, Procept maintains a competitive edge, fostering both adoption and trust within the healthcare community while steadily driving their growth and financial success.
Procept Biorobotics Corp. is a pioneering force in the medical technology landscape, blending innovative engineering with clinical insights to address some of the most pressing challenges in urology. Founded with a vision to revolutionize surgical care, the company developed the AquaBeam Robotic System, an advanced medical platform that leverages robotic precision and real-time ultrasound imaging. This system is primarily employed in performing Aquablation therapy, a minimally invasive treatment designed to alleviate symptoms of benign prostatic hyperplasia (BPH). By integrating robotics and imaging, Procept offers a solution that enhances the accuracy of prostate tissue removal while minimizing risks and downtime for patients—a significant advancement over conventional methods.
Revenue generation for Procept Biorobotics centers on the sales of their AquaBeam systems, along with consumables and service contracts that provide ongoing support and upgrades for their hospital and clinical partners. Recognizing the critical nature of procedure efficiency and safety, the company also invests in broadening the application of its technology and frequently seeks endorsements through clinical trials and studies to validate their innovations. By ensuring their cutting-edge solutions meet the stringent demands of healthcare professionals and patients alike, Procept maintains a competitive edge, fostering both adoption and trust within the healthcare community while steadily driving their growth and financial success.
Strong Revenue Growth: Q3 revenue reached $83.3 million, up 43% year-over-year, with continued momentum in both U.S. and international markets.
System Sales Acceleration: Sold 58 capital systems in Q3, driven by strong U.S. demand and stable capital pricing despite hospitals taking longer to finalize purchases.
Utilization Focus: Utilization growth in Q3 was in the low single digits, mainly due to slower ramp-up of new HYDROS systems; management is addressing this with targeted initiatives.
Updated 2025 Guidance: Full-year 2025 revenue remains guided at $325.5 million, with slight downward adjustment in Q4 handpiece sales due to inventory optimization.
2026 Revenue Outlook: Early guidance for 2026 revenue is $410–430 million, reflecting continued growth and some procedural headwinds in the first half due to organizational changes.
Profitability Path: Management reiterated commitment to investing for growth but remains confident in the path toward profitability, with no major disruption expected from increased spending.
International Strength: International revenue grew 53% in Q3, and full-year 2025 international revenue guidance was raised to $37.5 million.
Leadership & Strategy: New CEO Larry Wood brings focus on therapy awareness, patient activation, and organizational realignment to accelerate utilization and long-term growth.
